Session 2:Mutational discordance: the big challenge in personalized treatments – any solutions? by Kousgaard, Sabrina Just et al.
 
  
 
Aalborg Universitet
Session 2
Mutational discordance: the big challenge in personalized treatments – any solutions?
Kousgaard, Sabrina Just; Kirk, Karina Frahm; Nielsen, Hans Linde; Thorlacius-Ussing, Ole
Published in:
Colorectal Disease
DOI (link to publication from Publisher):
10.1111/codi.14079
Publication date:
2018
Document Version
Accepted author manuscript, peer reviewed version
Link to publication from Aalborg University
Citation for published version (APA):
Kousgaard, S. J., Kirk, K. F., Nielsen, H. L., & Thorlacius-Ussing, O. (2018). Session 2: Mutational discordance:
the big challenge in personalized treatments – any solutions? Colorectal Disease, 20(S4), 49-51.
https://doi.org/10.1111/codi.14079
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: November 24, 2020
1 
Session 2: Are we treating the correct patients? 
Mutational discordance: the big challenge in personalised 
treatments - any solutions? 
Speaker: Prof C Eng 
Muhammed Siddiqui, Manish Chand, Cathy Eng, Amir Mehdizadeh, Alex Mirnezami, 
Gina Brown 
Name & 
initials 
Qualifications Email address Main appointment & 
Institution(s) 
Muhammed 
Siddiqui 
(MS) 
MBChB, 
MRCS 
md0u812a@mac.co
m 
Research Fellow  
The Royal Marsden NHS 
Foundation Trust and 
Croydon University Hospital, 
U.K. 
Manish 
Chand (MC) 
BSc MBBS 
MBA FRCS 
PhD 
Manish.chand@uclh
.nhs.uk 
Consultant Colorectal 
Surgeon, University College 
London Hospital, U.K.  
Cathy Eng M.D., FACP ceng@mdanderson.
org 
Professor, Department of 
Gastrointestinal (GI) Medical 
Oncology, Division of Cancer 
Medicine, The University of 
Texas MD Anderson Cancer 
Center, Houston, TX, U.S.A. 
Amir 
Mehdizadeh 
AMehdizadeh@mda
nderson.org 
Senior Research Data 
Coordinator 
Department of 
Gastrointestinal (GI) Medical 
Oncology, Division of Cancer 
Medicine, The University of 
Texas MD Anderson Cancer 
Center, Houston, TX, U.S.A. 
Alex 
Mirnezami 
(AM) 
BSc BM PhD 
PCME FRCS 
(England) 
A.H.Mirnezami@sot
on.ac.uk 
Professor of Surgical 
Oncology, Consultant 
General and Colorectal 
Surgeon 
University of Southampton, 
U.K. 
Gina Brown 
(GB) 
MBBS, 
MRCP, 
FRCR, MD 
gina.brown@rmh.nh
s.uk
Consultant Radiologist  
The Royal Marsden NHS 
Foundation Trust, U.K. 
This is the peer reviewed version of the following article: Siddiqui, M., Chand, M., Eng, C., Mehdizadeh, A., Mirnezami, A. and Brown, 
G. (2018), Session 2: Mutational discordance: the big challenge in personalized treatments – any solutions?. Colorectal Dis, 20: 
49-51, which has been published in final form at https://doi.org/10.1111/codi.14079. This article may be used for non-commercial 
purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
2 
 
Honorary Professor of 
Gastrointestinal Cancer 
Imaging  
Imperial College London 
  
Corresponding author:  
Mr Muhammed Siddiqui  
md0u812a@mac.com 
 
Disclosures  
The authors have no conflict of interest.  
 
Word count excluding abstract, references, tables, figures and legends 
1397 
  
3 
 
Abstract 
The great challenge for oncologists treating patients developing or progressing with 
metastatic disease is to be able to offer a truly personalised and targeted therapy 
that can have an early and meaningful effect on the course of the disease. At 
present, the known molecular markers are limited in their frequency and reliability in 
determining the use of newer chemotherapies. Prof Eng discusses the challenges 
faced in ensuring timely and effective treatments based on the molecular profile of 
the tumour and discussed the potential role of real time analysis of mutational 
changes in the tumour when progression occurs.  
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I have been asked to discuss mutational discordance, the challenge in personalised 
therapies and is there a potential solution for our patients?  
 
There have been some new drugs that have been approved recently; many of these 
are variants of anti-VEGF and anti-EGFR therapies. We have also noticed the 
development of molecular markers and their role in the treatment for our patients. 
But regardless, the overall survival for surgically ‘unresectable’ patients is still very 
poor with a reported 5-year survival of 13%. The TRIBE trial was recently updated 
indicating that the 5-year survival was 25% if one uses FOLFOXIRI and 
Bevacizumab[1], but obviously this is only feasible in select patients. So we have to 
look for other treatment options.  As a result we must enrol patients onto clinical 
trials.  
 
Historically CEA was used to detect tumour recurrence or progression but 
unfortunately 15-30% of patients with tumour recurrence or progression do not have 
an elevated CEA.  The best way to evaluate these patients is by diagnostic imaging, 
clinical benefit and additional blood tests. However as medical oncologists we are 
faced with what the patient is personally experiencing. Patients want to get started 
on treatment as soon as possible, especially if they are being treated for palliative 
purposes. They are often unwilling to wait for their tissue molecular marker analysis, 
which may be a minimum of 7-10 business days, or if not longer, should their tissue 
biopsy reside in a warehouse.  
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In the USA the majority of oncologists start their patients on Bevacizumab as a 
biologic agent often because the patient is unwilling to wait. We obviously have our 
own anxiety, especially when we see young patients who we want to initiate 
treatment for as soon as possible, patients with a high degree of tumour burden 
and/or those with the BRAF mutation tumour type that’s traditionally known to be a 
poor prognostic factor.  Historically, we know that the first regimen is usually the one 
that has the largest impact on the patient in regards to overall survival.  
 
Thus far we have no molecular markers for anti-VEGF therapy that are predictive 
markers for benefit of therapy but we know it is imperative to test for the KRAS 
tumour mutation status when considering anti-EGFR therapy[2], and we know that 
the BRAF mutation is an extremely poor prognostic marker[3].  
 
The PRIME trial saw our approach to the KRAS mutation include extended RAS 
analysis[4].   The KRAS mutation is present in about in 30-50% patients, but even 
with a KRAS wild-type (WT) tumour, there are about 15-20% additional RAS 
mutations which will impact patient care when we are considering anti-EGFR 
therapy.  
 
The FIRE-3 study compared FOLFIRI + Cetuximab vs. FOLFIRI + Bevacizumab with 
a primary endpoint of response rate[5].  An extended RAS analysis was completed 
and noted an overall improvement in overall survival if you provided anti-EGFR 
therapy to an all RAS WT patient. What I think is very important about this study is 
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that the BRAF mutant patients had extremely poor median OS regardless of the the 
regimen provided.  CALGB 80405 contradicts FIRE 3 study (unpublished data), 
when comparing FOLFOX or FOLFIRI with randomization to bevacizumab based 
therapy vs. cetuximab based therapy with essentially equivalent overall survival for 
both arms. Based upon these trials we now know that the KRAS mutation is not the 
only molecular marker that we should be considering. We must also consider 
extended RAS analysis and the BRAF mutation. 
 
Limitations 
There are limitations in regard to tumour mutation analysis.  It can be very difficult to 
obtain the original archival tissue especially if it resides in a warehouse or if it was 
obtained several years ago. Regarding the primary tumour, sometimes the amount 
of tissue is insufficient and the storage conditions obviously can impact upon tissue 
analysis. The potential for discordance of the primary and metastatic tumour is a 
concern, although traditionally, as mentioned earlier, KRAS has very high 
concordance (>90%)[3].  You may recall the New England Journal of Medicine paper 
(2012) which presented a renal cell carcinoma patient which had significant intra-
tumoural heterogeneity within one patient[6].  
 
Another option is a fresh tissue biopsy, but this is results in additional time and cost 
associated with another invasive procedure, including scheduling the procedure and 
deciding upon which metastatic site to biopsy.  
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There is high concordance for KRAS, BRAF and PIK3CA but mild to moderate 
discordance for PTEN and CMET. Although CMET has not found a role yet in 
colorectal cancer, it appears to be a late event. So it is reasonable to ask what other 
options we have.  
 
Future potential options  
One of the potential roles for an evaluation is the so-called liquid biopsy. This is a 
non-invasive alternative to tumour mutation analysis that allows real-time capture of 
biologic changes within the patient and may be more representative of the current 
tumour mutation state allowing us potentially to detect the development of treatment 
resistance.  
 
We have all seen the KRAS WT type patient who started on anti-EGFR therapy and 
then eventually progress. There have been small studies that have indicated that the 
mutation status may change in associated with progression. Is it potentially quicker? 
Obviously that would be very helpful and may impact the initial treatment approach; it 
may change the way we perform diagnostic imaging and the timeframes to when we 
evaluate our patients and especially beneficial when we have a patient with a normal 
CEA. Could this be potentially more cost effective than what we are currently doing?  
 
Fresh tissue biopsies are expensive. When considering circulating free DNA, it is not 
only elevated in cancer patients but is also elevated in inflammation, trauma and 
sepsis. But we do know that circulating free DNA is 4-5 times higher in cancer 
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patients compared to controls due to either secretion, apoptosis or necrosis[7]. We 
can also detect other point mutations, copy number variations and structural 
rearrangements. This is very helpful in the setting when a patient has had a 
metastatic resection, especially if we could find a non-invasive approach to detect 
early relapse instead of just relying on diagnostic imaging. Obviously if the patient is 
currently on treatment (for example anti-EGFR therapy), use of cfDNA may indicate 
early signs of resistance rather relying on diagnostic imaging. Could we possibly use 
this as another alternative? 
 
There are limitations to liquid biopsy at this time.  There’s still some debate as to 
whether you use serum versus plasma although the majority of studies have 
suggested plasma is better [8]. There’s still some variability in DNA extraction and 
this may result in a variability of about 50% between yields. It’s very important to 
capture all the DNA fractions and obviously the smaller fractions may be the most 
informative from the primary and metastatic site. Currently, there is no overall 
consensus about storage or approach to these samples. There are some very recent 
publications indicating there is significant variation in technique and the majority of 
studies have a sensitivity of 5% or less although BEAMing is more sensitive. 
BEAMING isolates DNA and then amplified using magnetic beads, undergoes PCR, 
flow cytometry and then it quantitates the mutant versus wild type. Hotspot mutations 
are identified in specified genes so it has a sensitivity of less than 0.1%.  Therefore, 
you can identify one mutant allele in 10000 WT alleles.  
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In conclusion liquid biopsy is very promising, but is still not standardized, and needs 
to be validated in large prospective studies and to be made widely available at a 
reasonable cost. Obviously this may vary based upon technique and currently at this 
time we would still recommend using cfDNA in conjunction with diagnostic imaging. 
cfDNA is not considered a standard of care, but it is definitely intriguing. 
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Summary of the key points  
 Currently there are no predictive markers for the benefit of anti-VEGF therapy. 
 It is imperative to test for the KRAS tumour mutation status when considering 
anti-EGFR therapy  
 BRAF mutation is an extremely poor prognostic marker.  
 Extended RAS analysis should also be considered.  
 The potential for discordance of the primary and metastatic tumour is a 
concern, although traditionally KRAS has very high concordance (>90%). 
 Small studies have indicated that the patient’s mutation status may change 
with progression.  
 Use of cfDNA may indicate early signs of resistance rather relying on 
diagnostic imaging. 
 Liquid biopsy is very promising, but is still not standardized, and needs to be 
validated in large prospective studies and to be made widely available at a 
reasonable cost. 
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